Prognostic value of various summary measures of prostate-specific antigen (PSA) kinetics for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy (TROPIC trial).

被引：0
|
作者：
Legrand, Catherine
Oudard, Stephane
Sartor, A. Oliver
De Bono, Johann Sebastian
Shen, Liji
Machiels, Jean-Pascal H.
机构：
[1] Catholic Univ Louvain, Inst Stat Biostat & Sci Actuarielles, B-1348 Louvain, Belgium
[2] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[3] Tulane Canc Ctr, New Orleans, LA USA
[4] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[5] Sanofi Aventis, Malvern, PA USA
[6] Catholic Univ Louvain, Ctr Canc, B-1200 Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16010
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916
    Hussain, M. H.
    Goldman, B.
    Tangen, C. M.
    Higano, C. S.
    Petrylak, D. P.
    Crawford, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Prognostic value of PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the COU-AA-302 trial.
    Lorente, David
    Lozano, Rebeca
    de Velasco, Guillermo
    De Julian, Maria
    Rodrigo, Miguel
    Sanchez, Angel L.
    Di Capua, Carlos
    Castro, Elena
    Sanchez Hernandez, Alfredo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
    Nuhn, Philipp
    Vaghasia, Ajay M.
    Goyal, Jatinder
    Zhou, Xian C.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    BJU INTERNATIONAL, 2014, 114 (6B) : E11 - E17
  • [35] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] DENOSUMAB PROLONGS BONE-METASTASIS-FREE SURVIVAL IN MEN WITH NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PRESENTING WITH AGGRESSIVE PROSTATE-SPECIFIC ANTIGEN KINETICS: A POST HOC SUBSET ANALYSIS
    Marx, G. M.
    Smith, M. R.
    Saad, F.
    Shore, N. D.
    Oudard, S.
    Miller, K.
    Tombal, B.
    Sieber, P.
    Fizazi, K.
    Van Veldhuizen, P. J.
    Damiao, R.
    Morote, J.
    Feng, A.
    Dansey, R.
    Goessl, C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 45 - 45
  • [37] 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide
    Carles, J.
    Alonso, T.
    Mellado Gonzalez, B.
    Mendez Vidal, M. J.
    Vazquez Estevez, S.
    Gonzalez del Alba, A.
    Piulats, J. M.
    Borrega Garcia, P.
    Gallardo, E.
    Morales Barrera, R.
    Paredes, P.
    Reig, O.
    Garcias de Espana, C.
    Collado, R.
    Bonfill, T.
    Suarez, C.
    Malfettone, A.
    Garde, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S525 - S526
  • [38] The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience.
    Poon, Darren M. C.
    Wong, Kenneth C. W.
    Chan, T. W.
    Law, Kitty
    Chan, Kuen
    Lee, Ka Chai
    Lee, Conrad
    Ting, Chan Fong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [39] Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.
    Roy, Soumyajit
    Malone, Shawn
    Sun, Yilun
    Wallis, Christopher J. D.
    Kishan, Amar Upadhyaya
    Morgan, Scott C.
    Gebrael, Georges
    Swami, Umang
    Jia, Angela
    Brown, Jason R.
    Saad, Fred
    Agarwal, Neeraj
    Spratt, Daniel Eidelberg
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 126 - 126
  • [40] Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study
    Du, Hong
    Xie, Wenjuan
    Chen, Wenqiang
    Wang, Yu
    Liao, Yong
    Qiu, Mingxing
    Li, Jun
    FRONTIERS IN ONCOLOGY, 2024, 14
12345